Roth Cuts PT on Synta Pharma (SNTA) to $20; Still Attractively Priced Given Ganetespib Potential
Tweet Send to a Friend
Roth Capital is paring-back its price target on Synta Pharmaceuticals (Nasdaq: SNTA) from $27 to $20 and maintains a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
